Almost three years ago, I warned about the emerging trend of copay accumulators and outlined the costly consequences for patients.
I’m sad to report that the latest data show a startling acceleration in the adoption of copay accumulator adjustment and the closely related copay maximizer.
Within the next year, more than 80% of commercially insured beneficiaries will be in plans with these benefit designs—although not all plan sponsors will have fully implemented them.
Accumulators, maximizers, and copay support programs are inefficient solutions to flaws in the U.S. drug channel system. That’s why patient groups and provider organizations are pushing back against them.
Alas, our divided Congress seems unlikely to provide any relief. Read on for the full details.
Drug Channels Institute will host an exclusive live webinar, Drug Channels Outlook 2021, on December 18, 2020, from 12:00 p.m. to 1:15 p.m. ET. CLICK HERE TO LEARN MORE AND SIGN UP.
Source: Post feed
